Faculty Opinions recommendation of Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.

2017 ◽  
Author(s):  
Paola Gehrig
Keyword(s):  
Endometrial Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Pi3k Inhibitor

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

2015 ◽  
Vol 136 (2) ◽  
pp. 246-253 ◽  
Author(s):  
Ursula Matulonis ◽  
Ignace Vergote ◽  
Floor Backes ◽  
Lainie P. Martin ◽  
Scott McMeekin ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Pi3k Inhibitor

Phase II study of the PI3K inhibitor BKM120 monotherapy in patients with advanced or recurrent endometrial carcinoma: ENDOPIK, GINECO Study.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 5588-5588 ◽  
Author(s):  
Pierre-Etienne Heudel ◽  
Michel Fabbro ◽  
Celia Roemer-Becuwe ◽  
Isabelle Treilleux ◽  
Marie-Christine Kaminsky ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Pi3k Inhibitor

scholarly journals Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group

2017 ◽  
Vol 116 (3) ◽  
pp. 303-309 ◽  
Author(s):  
P-E Heudel ◽  
M Fabbro ◽  
C Roemer-Becuwe ◽  
M C Kaminsky ◽  
A Arnaud ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Pi3k Inhibitor ◽  
Type I ◽  
Type Ii

Chemotherapy plus Sequential Hormonal Therapy for Advanced and Recurrent Endometrial Carcinoma: A Phase II Study

1996 ◽  
Vol 60 (3) ◽  
pp. 462-467 ◽  
Author(s):  
Donna M. Pinelli ◽  
James V. Fiorica ◽  
William S. Roberts ◽  
Mitchel S. Hoffman ◽  
Santo V. Nicosia ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Phase Ii ◽  
Hormonal Therapy ◽  
Phase Ii Study

Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study

2006 ◽  
Vol 103 (2) ◽  
pp. 523-526 ◽  
Author(s):  
Paula M. Fracasso ◽  
John A. Blessing ◽  
Kelly L. Molpus ◽  
Lisa M. Adler ◽  
Joel I. Sorosky ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Second Line ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

Dactinomycin in the Treatment of Recurrent or Persistent Endometrial Carcinoma: A Phase II Study of the Gynecologic Oncology Group

1999 ◽  
Vol 75 (3) ◽  
pp. 473-475 ◽  
Author(s):  
David H. Moore ◽  
John A. Blessing ◽  
Charles Dunton ◽  
Richard E. Buller ◽  
Gary C. Reid
Keyword(s):  
Endometrial Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Oncology Group

A phase II study of trabectedin (ET-743) as a second line therapy in patients with persistent or recurrent endometrial carcinoma

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 5086-5086 ◽  
Author(s):  
D. S. McMeekin ◽  
G. Manikas ◽  
M. Crispens ◽  
A. M. Orza ◽  
P. Braly ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document